Scholar Rock Holdings has Rock Solid Growth Prospects!
Scholar Rock Holding (NASDAQ: SRRK), a clinical-stage biopharmaceutical Company, announced the grant of a Fast-Track Designation for apitegromab, a selective inhibitor of myostatin activation, intended for the treatment of Spinal Muscular Atrophy (SMA) by the U.S. Food and Drug Administration (FDA). The candidate has previously...
